2025 Q4 -tulosraportti
UUTTA
1 päivä sitten1 t 1 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,15%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 366 709
Myynti
Määrä
2 364 815
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 99 | - | - | ||
| 1 | - | - | ||
| 80 | - | - | ||
| 1 747 | - | - | ||
| 753 | - | - |
Ylin
297VWAP
Alin
281,65VaihtoMäärä
3 879,7 13 243 375
VWAP
Ylin
297Alin
281,65VaihtoMäärä
3 879,7 13 243 375
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 21 000 | 21 000 | 0 | 21 000 |
| DnB Bank ASA | 10 000 | 10 000 | 0 | 10 000 |
| Danske Bank A/S | 46 000 | 46 000 | 0 | 46 000 |
| Nordea Bank Abp | 62 | 62 | 0 | 62 |
| Anonyymi | 13 166 313 | 13 166 313 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 21 000 | 21 000 | 0 | 21 000 |
| DnB Bank ASA | 10 000 | 10 000 | 0 | 10 000 |
| Danske Bank A/S | 46 000 | 46 000 | 0 | 46 000 |
| Nordea Bank Abp | 62 | 62 | 0 | 62 |
| Anonyymi | 13 166 313 | 13 166 313 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q4 -tulosraportti | 5.2. | |
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9 min sittenAI Overview Yes, Hims & Hers Health, Inc. has on several occasions during 2025 and in early 2026 been subject to scrutiny and warnings from the US Food and Drug Administration (FDA). FirstWord Pharma FirstWord Pharma +1 Here is a summary of the situation based on the latest reports: FDA Warnings and Scrutiny Warning Letter (September 2025): FDA sent a warning letter to Hims & Hers regarding their marketing of "compounded" (mixed/custom-made) GLP-1 products (weight-loss drugs similar to Ozempic/Wegovy). FDA considered the marketing to be "false or misleading" as it gave the impression that these copies were FDA-approved or equivalent to the original drugs that had undergone stringent clinical trials. Focus on "Compounded" drugs: In early 2026, Hims & Hers launched its own version of a Wegovy copy in pill form. FDA has warned that these "compounded" products are not approved by the agency and have not undergone the same safety and efficacy testing. Reports of side effects: FDA has reported side effects and dosing errors linked to these types of substances (semaglutide) from pharmacies, which has increased scrutiny. Reuters Reuters +5 Other Legal and Regulatory Challenges Legal conflict with Novo Nordisk (2026): Novo Nordisk, the manufacturer of Wegovy, has accused Hims & Hers of illegal mass production of copies and threatened legal action, calling it a "significant patient risk". FTC investigation (2025): Hims & Hers has also been under scrutiny by the Federal Trade Commission (FTC) regarding its subscription services and whether it has been too difficult for customers to cancel subscriptions. CNBC CNBC +3 Hims & Hers' Response Hims & Hers has defended its operations by stating that they offer "personalized" dosages and formulations that meet patient needs, and that they use licensed pharmacies to produce the products. PBS PBS +1 In summary, Hims & Hers has been reported and warned by the FDA for misleading marketing and for selling unapproved copies of popular weight-loss drugs.
·1 t sittenIt will surely get a rise again !! he he
·12 min sittenNot worth 300... currently around 250... they will lose -6% this year as they predict. And at the end of the year patents expire in Canada, China etc.
·1 t sittenI think it's scandalous that Kåre Schultz, who sits on the board at Hims and Hers, has not protested against the launch of the illegal weight loss pill that Hims and Hers will launch. That stinks, Kåre. Just because you didn't become the top boss of Novo, it doesn't suit you to stab your old company in the back. The company that made you a multi-millionaire. Ugh, you should be ashamed of yourself. Hope you sleep well
·1 t sittenBeginner question: I bought my first Novo shares in January, and more today. Do I get dividends for all shares (or none of them) when dividends are paid out in March? Or do you have to have owned them for a longer time? Thanks in advance for the help
·1 t sittenYou must have and own them by 26 March at the latest. 27 March is the ex-date. So yes, you get for all shares you have at market close 26 March.
·2 t sittenLast week the price was at 400 and we were dissatisfied when it closed before the weekend at 375. Today it closes at 295 and optimism is blooming. Novo is a bit of a Danish rollercoaster.
56 min sitten56 min sittenI really hope we will get to 400 again one day. I regret not selling when we got there last time
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
1 päivä sitten1 t 1 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,15%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 min sittenAI Overview Yes, Hims & Hers Health, Inc. has on several occasions during 2025 and in early 2026 been subject to scrutiny and warnings from the US Food and Drug Administration (FDA). FirstWord Pharma FirstWord Pharma +1 Here is a summary of the situation based on the latest reports: FDA Warnings and Scrutiny Warning Letter (September 2025): FDA sent a warning letter to Hims & Hers regarding their marketing of "compounded" (mixed/custom-made) GLP-1 products (weight-loss drugs similar to Ozempic/Wegovy). FDA considered the marketing to be "false or misleading" as it gave the impression that these copies were FDA-approved or equivalent to the original drugs that had undergone stringent clinical trials. Focus on "Compounded" drugs: In early 2026, Hims & Hers launched its own version of a Wegovy copy in pill form. FDA has warned that these "compounded" products are not approved by the agency and have not undergone the same safety and efficacy testing. Reports of side effects: FDA has reported side effects and dosing errors linked to these types of substances (semaglutide) from pharmacies, which has increased scrutiny. Reuters Reuters +5 Other Legal and Regulatory Challenges Legal conflict with Novo Nordisk (2026): Novo Nordisk, the manufacturer of Wegovy, has accused Hims & Hers of illegal mass production of copies and threatened legal action, calling it a "significant patient risk". FTC investigation (2025): Hims & Hers has also been under scrutiny by the Federal Trade Commission (FTC) regarding its subscription services and whether it has been too difficult for customers to cancel subscriptions. CNBC CNBC +3 Hims & Hers' Response Hims & Hers has defended its operations by stating that they offer "personalized" dosages and formulations that meet patient needs, and that they use licensed pharmacies to produce the products. PBS PBS +1 In summary, Hims & Hers has been reported and warned by the FDA for misleading marketing and for selling unapproved copies of popular weight-loss drugs.
- ·1 t sittenIt will surely get a rise again !! he he·12 min sittenNot worth 300... currently around 250... they will lose -6% this year as they predict. And at the end of the year patents expire in Canada, China etc.
- ·1 t sittenI think it's scandalous that Kåre Schultz, who sits on the board at Hims and Hers, has not protested against the launch of the illegal weight loss pill that Hims and Hers will launch. That stinks, Kåre. Just because you didn't become the top boss of Novo, it doesn't suit you to stab your old company in the back. The company that made you a multi-millionaire. Ugh, you should be ashamed of yourself. Hope you sleep well
- ·1 t sittenBeginner question: I bought my first Novo shares in January, and more today. Do I get dividends for all shares (or none of them) when dividends are paid out in March? Or do you have to have owned them for a longer time? Thanks in advance for the help·1 t sittenYou must have and own them by 26 March at the latest. 27 March is the ex-date. So yes, you get for all shares you have at market close 26 March.
- ·2 t sittenLast week the price was at 400 and we were dissatisfied when it closed before the weekend at 375. Today it closes at 295 and optimism is blooming. Novo is a bit of a Danish rollercoaster.56 min sitten56 min sittenI really hope we will get to 400 again one day. I regret not selling when we got there last time
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 366 709
Myynti
Määrä
2 364 815
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 99 | - | - | ||
| 1 | - | - | ||
| 80 | - | - | ||
| 1 747 | - | - | ||
| 753 | - | - |
Ylin
297VWAP
Alin
281,65VaihtoMäärä
3 879,7 13 243 375
VWAP
Ylin
297Alin
281,65VaihtoMäärä
3 879,7 13 243 375
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 21 000 | 21 000 | 0 | 21 000 |
| DnB Bank ASA | 10 000 | 10 000 | 0 | 10 000 |
| Danske Bank A/S | 46 000 | 46 000 | 0 | 46 000 |
| Nordea Bank Abp | 62 | 62 | 0 | 62 |
| Anonyymi | 13 166 313 | 13 166 313 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 21 000 | 21 000 | 0 | 21 000 |
| DnB Bank ASA | 10 000 | 10 000 | 0 | 10 000 |
| Danske Bank A/S | 46 000 | 46 000 | 0 | 46 000 |
| Nordea Bank Abp | 62 | 62 | 0 | 62 |
| Anonyymi | 13 166 313 | 13 166 313 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q4 -tulosraportti | 5.2. | |
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 |
2025 Q4 -tulosraportti
UUTTA
1 päivä sitten1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q4 -tulosraportti | 5.2. | |
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
4,15%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 min sittenAI Overview Yes, Hims & Hers Health, Inc. has on several occasions during 2025 and in early 2026 been subject to scrutiny and warnings from the US Food and Drug Administration (FDA). FirstWord Pharma FirstWord Pharma +1 Here is a summary of the situation based on the latest reports: FDA Warnings and Scrutiny Warning Letter (September 2025): FDA sent a warning letter to Hims & Hers regarding their marketing of "compounded" (mixed/custom-made) GLP-1 products (weight-loss drugs similar to Ozempic/Wegovy). FDA considered the marketing to be "false or misleading" as it gave the impression that these copies were FDA-approved or equivalent to the original drugs that had undergone stringent clinical trials. Focus on "Compounded" drugs: In early 2026, Hims & Hers launched its own version of a Wegovy copy in pill form. FDA has warned that these "compounded" products are not approved by the agency and have not undergone the same safety and efficacy testing. Reports of side effects: FDA has reported side effects and dosing errors linked to these types of substances (semaglutide) from pharmacies, which has increased scrutiny. Reuters Reuters +5 Other Legal and Regulatory Challenges Legal conflict with Novo Nordisk (2026): Novo Nordisk, the manufacturer of Wegovy, has accused Hims & Hers of illegal mass production of copies and threatened legal action, calling it a "significant patient risk". FTC investigation (2025): Hims & Hers has also been under scrutiny by the Federal Trade Commission (FTC) regarding its subscription services and whether it has been too difficult for customers to cancel subscriptions. CNBC CNBC +3 Hims & Hers' Response Hims & Hers has defended its operations by stating that they offer "personalized" dosages and formulations that meet patient needs, and that they use licensed pharmacies to produce the products. PBS PBS +1 In summary, Hims & Hers has been reported and warned by the FDA for misleading marketing and for selling unapproved copies of popular weight-loss drugs.
- ·1 t sittenIt will surely get a rise again !! he he·12 min sittenNot worth 300... currently around 250... they will lose -6% this year as they predict. And at the end of the year patents expire in Canada, China etc.
- ·1 t sittenI think it's scandalous that Kåre Schultz, who sits on the board at Hims and Hers, has not protested against the launch of the illegal weight loss pill that Hims and Hers will launch. That stinks, Kåre. Just because you didn't become the top boss of Novo, it doesn't suit you to stab your old company in the back. The company that made you a multi-millionaire. Ugh, you should be ashamed of yourself. Hope you sleep well
- ·1 t sittenBeginner question: I bought my first Novo shares in January, and more today. Do I get dividends for all shares (or none of them) when dividends are paid out in March? Or do you have to have owned them for a longer time? Thanks in advance for the help·1 t sittenYou must have and own them by 26 March at the latest. 27 March is the ex-date. So yes, you get for all shares you have at market close 26 March.
- ·2 t sittenLast week the price was at 400 and we were dissatisfied when it closed before the weekend at 375. Today it closes at 295 and optimism is blooming. Novo is a bit of a Danish rollercoaster.56 min sitten56 min sittenI really hope we will get to 400 again one day. I regret not selling when we got there last time
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 366 709
Myynti
Määrä
2 364 815
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 99 | - | - | ||
| 1 | - | - | ||
| 80 | - | - | ||
| 1 747 | - | - | ||
| 753 | - | - |
Ylin
297VWAP
Alin
281,65VaihtoMäärä
3 879,7 13 243 375
VWAP
Ylin
297Alin
281,65VaihtoMäärä
3 879,7 13 243 375
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 21 000 | 21 000 | 0 | 21 000 |
| DnB Bank ASA | 10 000 | 10 000 | 0 | 10 000 |
| Danske Bank A/S | 46 000 | 46 000 | 0 | 46 000 |
| Nordea Bank Abp | 62 | 62 | 0 | 62 |
| Anonyymi | 13 166 313 | 13 166 313 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 21 000 | 21 000 | 0 | 21 000 |
| DnB Bank ASA | 10 000 | 10 000 | 0 | 10 000 |
| Danske Bank A/S | 46 000 | 46 000 | 0 | 46 000 |
| Nordea Bank Abp | 62 | 62 | 0 | 62 |
| Anonyymi | 13 166 313 | 13 166 313 | 0 | 0 |